These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34998921)

  • 1. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA; Jaspers M; Peters HJW; Dickhoff BHJ
    Adv Drug Deliv Rev; 2022 Oct; 189():114527. PubMed ID: 36070848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
    Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
    Elsayed MMA; Alfagih IM; Brockbank K; Aodah AH; Ali R; Almansour K; Shalash AO
    Int J Pharm; 2024 Apr; 655():123966. PubMed ID: 38452834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the extra-fine particle fraction of levofloxacin embedded in excipient matrix formulations for dry powder inhaler using response surface methodology.
    Tse JY; Kadota K; Imakubo T; Uchiyama H; Tozuka Y
    Eur J Pharm Sci; 2021 Jan; 156():105600. PubMed ID: 33075466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
    Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
    Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M
    Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Process Modeling Capabilities for Dry Powder Operations for Inhaled Formulations.
    Lou H; Ding L; Wu T; Li W; Khalaf R; Smyth HDC; Reid DL
    Mol Pharm; 2023 Nov; 20(11):5332-5344. PubMed ID: 37783568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
    Khanal D; Kim J; Zhang J; Ke WR; Holl MMB; Chan HK
    Int J Pharm; 2023 Feb; 632():122563. PubMed ID: 36586629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing Dry Powder Inhaler Formulations.
    Morton DAV; Barling D
    J Aerosol Med Pulm Drug Deliv; 2024 Apr; 37(2):90-99. PubMed ID: 38640447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols.
    Muralidharan P; Mallory EK; Malapit M; Phan H; Ledford JG; Hayes D; Mansour HM
    RSC Adv; 2020 Nov; 10(68):41846-41856. PubMed ID: 33391731
    [No Abstract]   [Full Text] [Related]  

  • 16. A Novel Technique to Assess Drug Substance Particle Size in a Complex Inhaled Formulation.
    Dobson DP; Saggu M; Pellett JD; Tso J
    J Pharm Sci; 2023 Sep; 112(9):2385-2388. PubMed ID: 37422282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
    Weers JG; Miller DP; Tarara TE
    AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
    Sun Y; Yu D; Li J; Zhao J; Feng Y; Zhang X; Mao S
    Eur J Pharm Biopharm; 2022 Oct; 179():47-57. PubMed ID: 36029939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
    Saboti D; Maver U; Chan HK; Planinšek O
    J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.